Skip to main content

Medipharm Labs Corp(LABS-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0650
Day High0.0650
Open:0.0650
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
Newsfile
Upcoming Meeting Dates - April 13, 2026
AllPennyStocks.com
International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase
International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase
GlobeNewswire
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
GlobeNewswire
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
GlobeNewswire
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
GlobeNewswire
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
GlobeNewswire
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
GlobeNewswire
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
GlobeNewswire
MediPharm Labs Completes First Shipment to France
GlobeNewswire
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
GlobeNewswire
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
Newswire.ca
/U P D A T E -- MediPharm Labs Corp./
Newswire.ca
MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees
The Globe and Mail
Insiders point to opportunity in Canadian cannabis
Cannabis plants grow inside of Thrive Cannabis' production facility in Simcoe, Ont. Tuesday, April 13, 2021. A group convened by the federal government to study the act that legalized cannabis is recommending the country review the excise taxes it charges pot companies. THE CANADIAN PRESS/Tara Walton
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
GlobeNewswire
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
GlobeNewswire
MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders
GlobeNewswire
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
GlobeNewswire
Apollo Capital Wins Proxy Contest at MediPharm Labs
GlobeNewswire
Leading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees
GlobeNewswire
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
GlobeNewswire
Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
GlobeNewswire
MediPharm Labs’ Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
Baystreet
Stocks in play: MediPharm Labs Corp.
GlobeNewswire
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of
Newswire.ca
Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results
Baystreet
Stocks in play: MediPharm Labs Corp.
Newswire.ca
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

Profile

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.